Tatva Chintan Pharma LTD IPO:GMP, Issue Price, Issue Size

0
58
Tatva Chintan Pharma Chem Ltd IPO
Rate this post

Tatva Chintan Pharma Ltd IPO all set to make a debut in the stock market with an issue size of 500 Cr and is one of the leading chemical manufacturing company that manufactures structure directing agents.   

Tatva Chintan Pharma LTD IPO -Overview  

Tatva Chintan Pharma Chem Limited IPO Issue Date         16-20 July 2021        
Tatva Chintan Pharma Chem Limited IPO Opening Date         29 July 2021        
Tatva Chintan Pharma Chem Limited IPO Face Value         INR 10 per share         
Tatva Chintan Pharma Chem Limited IPO Price         INR 1083 per share        
Tatva Chintan Pharma Chem Limited IPO Lot Size         13 Shares        
Issue Size         500 Cr        
Offer for sale         275 Cr     
Issue Type         Book built Issue IPO         
Listing At         BSE, NSE        
QIB Shares Offered           185.23 times        
NII (HNI) Shares         512.22 times        
Company Promoters         Ajaykumar Mansukhlal Patel, Chintan Nitinkumar Shah, and Snehkar Rasiklal Somani are the company promoters. 
DCX Systems LTD IPO: GMP, Issue Size, Lot size And Important Dates

Tatva Chintan Pharma LTD IPO-Tentative Dates         

Tatva Chintan Pharma Chem Limited IPO opening date         16 July 2021        
Tatva Chintan Pharma Chem Limited IPO closing date         20 July 2021        
Basis of Allotment         26 July 2021        
Initiation of Refunds         27 July 2021        
The credit of Shares to Demat        28 July 2021   
Tatva Chintan Pharma Chem Limited IPO Listing Date         29 July 2021   

Tatva Chintan Pharma Chem – Industry Overview.        

India’s Battery Electrolyte market stands at USD 0.35-0.4 Bn in 2019 projected to grow at 8-9% CAGR over the next half-decade to reach USD 0.55-0.65 Bn by the year 2024F. India’s battery electrolyte market is approximately 6-8% of the global battery electrolyte market. Automotive and Consumer Electronics comprise more than half of India’s market. The Automotive segment saw a drop in sales in the last 2 years; it is, however, expected to bounce back and grow exponentially. The demand for Hybrid vehicles and Electric Vehicles will in turn boost the demand from the Automotive and Transport industry. With a growing technologically savvy population and better standards of living, the demand for consumer electronics in the forms of Phones, Mobiles, Laptops, Music Players, Audio Assistants, and Reading Tablets among others is driving the Consumer Electronics market. 

Tatva Chintan Pharma LTD IPO – Company Overview   

 Tatva Chintan Pharma is specialty chemicals manufacturing company engaged in the manufacture of a diverse portfolio of structure directing agents (“SDAs”), phase transfer catalysts (“PTCs”), electrolyte salts for supercapacitor batteries and pharmaceutical and agrochemical intermediates, and other specialty chemicals(“PASC”). The Company is the largest and only commercial manufacturer of SDAs for zeolites in India. It also enjoys the second-largest position globally. In addition, the Company is one of the leading global producers of an entire range of PTCs in India and one of the key producers across the globe. As a manufacturer of specialty chemicals, they focus on the application of the products which form a key ingredient in the customers’ manufacturing and industrial processes.  For instance, the SDA and PTC products have various applications in green chemistry, which is pertinent considering the growing focus on green and sustainable technologies. 

 Tatva Chintan Pharma LTD IPO-Objectives         

  • Funding capital expenditures requirements for expansion of Dahej manufacturing facility. 
  • Funding capital expenditures requirements to upgrade R&D facilities in Vadodara. 
  • To meet general corporate purposes. 

Tatva Chintan Pharma LTD IPO – Financial Statements        

Particulars        31-Mar-21      31-Mar-20      31-Mar-19      
Total Assets        3,148.03 2,489.38 1,875.08 
Total Revenue        3,062.92 2,646.22 2,068.01 
Profit After Tax        522.62 377.89 205.43 

Tatva Chintan Pharma LTD IPO Strengths        

  • Leading manufacturer of structure-directing agents and phase transfer catalysts.  
  • Diversified product portfolio.  
  • Global market presence with a customer base across industries.  
  • Strategically located manufacturing facility in Gujarat with proximity to Hazira Port.  
  • Experienced promoters and team managers.  
  • Strong financial performance track record. 

Tatva Chintan Pharma LTD IPO Weakness         

  • Failure to comply with the quality standards and technical specifications prescribed by its institutional customer. 
  • Dependency on a limited number of supplies for certain raw materials. 

Company Contact Information

Tatva Chintan Pharma Chem Ltd
Plot No. 502 / 17, GIDC Estate, Ankleshwar,
Bharuch, Gujarat – 393002, India

Phone: +91 75730 46951
Email: cs@tatvachintan.com
Websitehttp://www.tatvachintan.com/

Tatva Chintan Pharma IPO Registrar



Phone: +91-22-4918 6270
Email: tatva.ipo@linkintime.co.in
Websitehttps://linkintime.co.in/

Tatva Chintan Pharma IPO Lead Manager(s)

  1. ICICI Securities Limited (Past IPO Performance)
  2. JM Financial Limited (Past IPO Performance)

LEAVE A REPLY

Please enter your comment!
Please enter your name here